<DOC>
	<DOCNO>NCT02317861</DOCNO>
	<brief_summary>The purpose study explore pharmacodynamics ( PD ) , pharmacokinetics ( PK ) , safety , tolerability multiple dos RDEA3170 administer combination febuxostat compare RDEA3170 administer alone febuxostat administer alone Japanese adult male subject gout asymptomatic hyperuricemia .</brief_summary>
	<brief_title>A PD/Safety Study RDEA3170 Combination With Febuxostat Treating Gout Asymptomatic Hyperuricemia Patients</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<mesh_term>Benzbromarone</mesh_term>
	<criteria>Screening serum uric acid level ≥ 8 mg/dL ; Body weight ≥ 50 kg body mass index ( BMI ) ≥ 18 ≤ 40 kg/m2 ; Free clinically significant disease medical condition , per Investigator 's judgment . History suspicion kidney stone ; Diagnosis benign prostatic hypertrophy ( BPH ) neurogenic bladder evidence BPH/neurogenic bladder thin urinary stream difficulty urination ; An estimate creatinine clearance &lt; 60 mL/min calculate CockcroftGault formula ; QTcF interval ( QT interval correct heart rate use Fridericia 's formula ) &gt; 450 msec Screening ; Receiving strong moderate Cytochrome P450 ( CYP ) 3A inhibitor pglycoprotein inhibitor , digoxin</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>